A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need ...

—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

Please provide your email address to receive an email when new articles are posted on . NCCN recommends osimertinib plus chemotherapy or lazertinib plus amivantamab-vmjw as first-line options for EGFR ...

The National Comprehensive Cancer Network’s newly updated non-small cell lung cancer guideline adds sevabertinib as a treatment option for some patients with advanced disease, makes datopotamab ...

LUNG CANCER continues to be the most common and deadly malignant tumor worldwide. 1 The main challenge to improve the poor survival rate (5-year survival of approximately 15%) of this disease is to ...

Reactions to low rates of molecular testing for patients with non-small cell lung cancer in community settings. Charu Aggarwal, M.D., MPH: Recent data show that there are many challenges. We saw ...

Please provide your email address to receive an email when new articles are posted on . National Comprehensive Cancer Network guidelines recommend all patients with advanced nonsquamous non-small cell ...

Two medical oncologists break down the role molecular testing has when treating NSCLC, from guidelines to common methods to barriers. Joshua Sabari, MD: I recommend testing up front. All patients with ...

Integrating plasma next-generation sequencing (NGS) alongside tissue testing when determining lung cancer diagnosis may improve outcomes for patients. Carrying out plasma next-generation sequencing ...

The US Food and Drug Administration (FDA) has granted approval for Thermo Fisher Scientific's Oncomine Dx Target Test as a treatment for non-small cell lung cancer (NSCLC). The test serves as a ...

Stephen Liu, MD: So, when you think of biomarker testing and the impact on treatment selection, molecular testing influences things from the very beginning because we’re going in two completely ...

"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...